Are you involved in biomedical research and interested in starting your own company? Would you like to learn about the career options in healthcare beyond academia? Would you like to hear about the experiences of others who have already chosen this path?
Biocat organizes the “Claus per Bioemprendre” introductory course in bioentrepreneurship to share the personal experiences of top bioentrepreneurs in Catalonia with students and researchers.
The course has three three-hour sessions, covering the role of entrepreneurship in biotechnology; the first steps in bioentrepreneurship, from concept to first rounds of funding; and the phases and partners that make up the life cycle of a biotechnology company. ¨Claus per Bioemprendre¨ 8th edition will take place in three sessions held on May 15, 22 and 29, 2018. The deadline for registration is May 11.
Participants will learn how entrepreneurship has shaped the development of biotechnology; they will learn how to detect good scientific ideas and when and why they are worth turning them into business; they will learn about the main business models of biotech startups and how they have evolved in recent years.
Tuesday, May 15, from 6:00 p.m. to 9:00 p.m.
6:00 – 6:30pm Registration and welcome
6:30 – 8:00pm Presentations
Lluis Ruiz-Ávila, CEO of Spherium Biomed
Laura Soucek, Founder and CEO of Peptomyc
Marc Ramis, Founder and CEO of Senolytic Therapeutics
Jordi Naval, Director of Strategy of Biocat (Moderator)
8:00 – 8:15pm Round table
8:15 – 9.00pm Cocktail networking
2nd session "Claus per Bioemprendre": 'The first steps: from the idea to the first rounds of financing'
3rd session "Claus per Bioemprendre": 'Life cycle of the biotechnology company: steps and partners that will accompany us along the way'
For questions & further information, please send an e-mail to Anna Rovira (events@biocat.cat) or feel free to call us (+34 93 310 33 69).
Organizer
|
Collaborators
|
|
Sponsor
Participants
With the support of:
* With the support of the Department of Enterprise and Knowledge and the co-financing of the ESF
